TRAW
Traws Pharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.55
+1.49%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.2x
Market Cap
$8.45M
MomentumView details →
1D Return
+1.49%
YTD Return
−51.33%
RSI (14)
44.0
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.2x
Market Cap
$8.45M
RSI (14)
44.0
MomentumView details →
1D Return
+1.49%
YTD Return
−51.33%
SummaryUpdated Mar 1, 2026
Traws Pharma, Inc. (NASDAQ:TRAW) is a clinical-stage biopharmaceutical company that was originally incorporated in 1998 as Onconova Therapeutics, Inc. before rebranding to its current name in April 2024. Headquartered in Newtown, Pennsylvania, the company focuses on developing small molecule oral therapies for two primary areas: respiratory viral diseases including COVID-19 and influenza, and various forms of cancer. As a clinical-stage biotech firm, Traws Pharma does not yet have approved commercial products and is currently advancing multiple drug candidates through various phases of clinical trials.
Similar companies
Latest newsMore news →
Traws Pharma reported its financial results for the quarter ended June 30, 2026, and provided business highlights including updates on its lead clinical programs and its April 2026 financing.21d agoTraws Pharma, Inc. elected Iain Dukes, Werner Cautreels, Trafford Clarke, John Leaman, and Nikolay Savchuck as directors, effective July 8, 2026.58d agoTraws Pharma deferred its planned Phase 2a human influenza challenge study of tivoxavir marboxil after a negative review by the UK's Medicines and Healthcare Products Regulatory Agency.84d ago